Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ViiV Healthcare

- PMLiVE

GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients

Final efficacy analysis confirms previous positive findings from interim analysis

- PMLiVE

EMA concludes GSK, Vir’s mAb can be used to treat high-risk COVID-19 patients

Recommendations can be used to support national advice prior to marketing authorisation

- PMLiVE

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

Sandoz, the generics division of Novartis, will pay $350m upfront for three established brands

- PMLiVE

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

Treatment could be transformative for around 260 million people living with disease

- PMLiVE

Medicago doses first patients with plant-derived COVID-19 vaccine

Study will evaluate candidate alone or in combination with an adjuvant

- PMLiVE

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

The five-year deal includes Sitryx’ two lead projects

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

GlaxoSmithKline reportedly looking to sell select antibiotic brands

Sale would fund R&D efforts in other key focus areas such as oncology

- PMLiVE

Moderna and GSK advance coronavirus vaccine candidates

Developments come amid rapidly growing cases across the globe

- PMLiVE

Researchers discover new antibiotic using AI

First antibiotic to be discovered using this method

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

dengue fever mosquito

NIH starts first trial of an antibody for malaria prevention

Results should be available in the first quarter of next year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links